|1.||Berzigotti, Annalisa: 8 articles (05/2015 - 05/2008)|
|2.||Abraldes, Juan G: 7 articles (01/2016 - 05/2008)|
|3.||Bosch, Jaime: 5 articles (05/2015 - 05/2008)|
|4.||Peck-Radosavljevic, Markus: 5 articles (02/2015 - 11/2007)|
|5.||Ferlitsch, Arnulf: 5 articles (02/2015 - 11/2007)|
|6.||García-Pagán, Juan Carlos: 4 articles (10/2015 - 06/2012)|
|7.||Reiberger, Thomas: 4 articles (02/2015 - 07/2011)|
|8.||Trauner, Michael: 4 articles (02/2015 - 07/2011)|
|9.||Bosch, Jaume: 3 articles (01/2016 - 06/2012)|
|10.||Kim, Moon Young: 3 articles (01/2015 - 09/2012)|
02/01/2015 - "We performed a systematic search of the MEDLINE database (articles published in full in English language from 1996 to October 2013) and related bibliography for studies reporting on the postoperative outcomes (3- and 5-year mortality and/or early clinical decompensation) of patients with HCC and compensated cirrhosis treated with surgery according to the presence or absence of CSPH. "
05/01/2011 - "This study assessed the prognostic value of a single HVPG measurement and Doppler-ultrasound (US) evaluation in patients with cirrhosis and CSPH. "
01/01/2016 - "Patients with subclinical PHT have less hyperdynamic circulation and significantly lower portal pressure reduction after acute β-blockade than those with CSPH, suggesting that β-blockers are more suitable to prevent decompensation of cirrhosis in patients with CSPH than in earlier stages. "
02/01/2015 - "This systematic review assesses the impact of CSPH on the outcome of HCC in patients with compensated cirrhosis treated with surgery. "
02/01/2015 - "New TE criteria allowed a better discrimination of reliable and non-reliable results for prediction of fibrosis and CSPH. "
11/01/2015 - "To assess the correlation between liver stiffness measurement (LSM) by real-time shear wave elastography (SWE) and hepatic venous pressure gradient (HVPG) and to investigate the diagnostic performance of SWE for predicting clinically significant and severe portal hypertension (CSPH and SPH). "
05/01/2015 - "Reliability criteria for RT-SWE were searched, and the accuracy of these techniques to identify HVPG ⩾10mmHg (clinically significant portal hypertension, CSPH) was tested and internally validated by bootstrapping analysis. "
02/01/2014 - "Seventy-four patients had clinically significant portal hypertension (CSPH), of whom 59 had severe portal hypertension (SPH). "
12/01/2013 - "CSPH and severe portal hypertension were defined as HVPG ≥10 and ≥12 mmHg, respectively. "
10/01/2012 - "We hypothesized that vWF-Ag levels may correlate with portal pressure, measured by hepatic venous pressure gradient (HVPG), and predict clinically significant portal hypertension (CSPH; HVPG ≥ 10 mmHg), decompensation and mortality. "
|3.||Liver Cirrhosis (Hepatic Cirrhosis)
06/01/2012 - "Recent studies suggest that TE may be used to screen for liver cirrhosis and clinically significant portal hypertension (≥ 10 mmHg; CSPH), whereas data on the clinical applicability of TE are limited. "
12/01/2013 - "LSM could be a non-invasive method for predicting CSPH and severe portal hypertension in Korean patients with liver cirrhosis."
|4.||Esophageal and Gastric Varices (Esophageal Varices)
12/01/2014 - "The aim was to compare ARFI, transient elastography (TE) and AST to platelet ratio index (APRI) for the noninvasive diagnosis of clinically significant portal hypertension (CSPH, hepatic venous pressure gradient; HVPG ≥ 10 mmHg) and esophageal varices (EV). "
01/01/2015 - "Key Messages: In compensated cirrhosis the presence of clinically significant portal hypertension [CSPH = hepatic venous pressure gradient (HVPG) ≥10 mm Hg] constitutes the most important independent predictor of several relevant clinical endpoints (formation of esophageal varices; first clinical decompensation). "
01/01/2013 - "Noninvasive methods are needed to identify clinically significant portal hypertension (CSPH) and esophageal varices (EVs) in patients with compensated cirrhosis. "
05/01/2008 - "We aimed to develop a model based on noninvasive variables for the prediction of clinically significant portal hypertension (CSPH) and of esophageal varices (EV) in patients with compensated liver disease. "
|5.||Varicose Veins (Varicose Vein)
01/01/2013 - "We assessed the ability of platelet count, spleen diameter, LS, and combinations of these factors (ie, ratio of platelet count to spleen size, and LS × spleen size/platelet count [LSPS]) to identify patients with CSPH and EV. The analysis included 2 new statistical models: the PH risk score and the varices risk score. "
01/01/2016 - "Hepatic venous pressure gradient (HVPG) and systemic hemodynamic were measured in 273 patients with compensated cirrhosis before and after intravenous propranolol (0.15 mg/kg): 194 patients had an HVPG ≥10 mm Hg (clinically significant PHT [CSPH]), with either no varices (n = 80) or small varices (n = 114), and 79 had an HVPG >5 and <10 mm Hg (subclinical PHT). "
06/15/2012 - "In nondiabetic patients with cirrhosis, HOMA-2 index is directly associated with the presence of CSPH and indirectly with varices, but does not allow either grading HVPG or predicting its response to propranolol."
|2.||Initiator Codon (Start Codon)
|3.||Messenger RNA (mRNA)
|4.||Aspartate Aminotransferases (Aspartate Transaminase)